Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCRX.L Regulatory News (CRX)

  • There is currently no data for CRX

Statement re Unsolicited Approach

2 Mar 2010 07:00

RNS Number : 9142H
Cyprotex PLC
02 March 2010
 



2 March 2010

 

 

Cyprotex PLC

("Cyprotex" or the "Company")

 

 

Statement re Unsolicited Approach

In light of the recent share price movements the Board of Cyprotex (AIM: CRX) announces that it has received a highly preliminary and unsolicited approach regarding a potential offer for the Company.

It should be noted that there is no certainty that an offer will be forthcoming.

This announcement has been made without the consent of the party who made the approach.

In accordance with Rule 2.10 of The City Code on Takeovers and Mergers (the 'Code'), Cyprotex confirms that, as at the date of this announcement it had 178,957,188 ordinary shares of 0.01 pence each in issue.

 

Enquiries:

 

Cyprotex PLC

 

Anthony Baxter CEO

016 2552 5100

 

ir@cyprotex.com

www.cyprotex.com

 

 

Execution Noble & Company Limited

 

John Llewellyn-Lloyd

020 7456 9191

 

Sam Reynolds

 

 

Public Relations

 

Financial Dynamics

 

Ben Brewerton

020 7831 3113

 

Ben Atwell

 

John Dineen

 

 

 

 

Dealing Disclosure Requirements

 

Under the provisions of Rule 8.3 of the City Code on Takeovers and Mergers (the 'Code'), if any person is, or becomes, 'interested' (directly or indirectly) in 1% or more of any class of 'relevant securities' of the Company, all 'dealings' in any 'relevant securities' of the Company (including by means of an option in respect of, or a derivative referenced to, any such 'relevant securities') must be publicly disclosed by no later than 3.30pm (London time) on the London business day following the date of the relevant transaction. This requirement will continue until the date on which the offer becomes, or is declared, unconditional as to acceptances, lapses or is otherwise withdrawn or on which the 'offer period' otherwise ends. If two or more persons act together pursuant to an agreement or understanding, whether formal or informal, to acquire an 'interest' in 'relevant securities' of the Company, they will be deemed to be a single person for the purpose of Rule 8.3.

 

Under the provisions of Rule 8.1 of the Code, all 'dealings' in 'relevant securities' of the Company by the Company or by any of its respective 'associates', must be disclosed by no later than 12.00 noon (London time) on the London business day following the date of the relevant transaction.

 

A disclosure table, giving details of the companies in whose 'relevant securities' 'dealings' should be disclosed, and the number of such securities in issue, can be found on the Takeover Panel's website at www.thetakeoverpanel.org.uk.

 

'Interests in securities' arise, in summary, when a person has long economic exposure, whether conditional or absolute, to changes in price or securities. In particular, a person will be treated as having an 'interest' by virtue of the ownership or control of securities, or by virtue of any option in respect of, or derivative referenced to, securities.

 

Terms in quotation marks are defined in the Code, which can be found on the Panel's website. If you are in any doubt as to whether or not you are required to disclose a 'dealing' under Rule 8, you should consult the Panel.

 

If you are in any doubt as to the application of Rule 8 to you, please contact an independent financial advisor authorised under the Financial Services and Markets Act 2000, consult the Panel's website at www.thetakeoverpanel.org.uk or contact the Panel on telephone number +44 20 7638 0129; fax +44 20 7236 7013.

 

The Directors of the Company accept responsibility for the information contained in this announcement. To the best of knowledge and belief of the Directors, who have taken all reasonable care to ensure such is the case, the information contained in this announcement is in accordance with the facts and does not omit anything likely to affect the import of such information.

 

Execution Noble & Company Limited is acting for the Company and for no-one else in connection with the possible offer for the Company and will not regard any other person as its client nor be responsible to anyone other than the Company for providing the protections afforded to clients of Execution Noble & Company Limited nor for providing advice in relation to the possible offer or any matter referred to herein. Execution Noble & Company Limited, is authorised and regulated by the Financial Services Authority in respect of regulated activities.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
OFDQLLBBBXFZBBQ
Date   Source Headline
21st Mar 20137:00 amRNSFinal Results
15th Mar 20137:00 amRNSNotice of Results
26th Feb 201312:05 pmRNSHolding(s) in Company
26th Feb 201312:05 pmRNSHolding(s) in Company
14th Feb 20137:00 amRNSLaunch of new cardiotoxicity service-eCiphrCardio
11th Jan 20137:00 amRNSIssue of Equity
13th Dec 20127:00 amRNSTrading Statement
30th Oct 20127:00 amRNSRe Agreement with Pfizer
29th Oct 20127:00 amRNSChange of NOMAD Name
16th Oct 20127:00 amRNSLicensing Agreement with Sigma Life Science
20th Sep 20127:00 amRNSCellCiphr Premier Launch
6th Sep 20127:00 amRNSHalf Yearly Report
6th Sep 20127:00 amRNSJoint Service Offering
4th Sep 20127:00 amRNSNotice of Results
4th Sep 20127:00 amRNSBoard Change
2nd Aug 20127:00 amRNSUpdated Regulatory Guidance Booklet
18th Jul 20121:49 pmRNSResult of AGM
21st Jun 20127:00 amRNSAlliance with Sirius Analytical
3rd May 20127:00 amRNSProduct Launch
22nd Mar 20127:00 amRNSFinal Results
12th Jan 20127:00 amRNSPre-Closed Trading Update
16th Dec 20117:00 amRNSSygnature Discovery and Cyprotex Extend Alliance
9th Nov 20117:00 amRNSProduct Upgrade
7th Nov 20117:00 amRNSExpansion of US Facility
29th Sep 20117:00 amRNSBoard Change
25th Aug 20117:00 amRNSHalf Yearly Report
8th Jul 20117:00 amRNSRe Agreement
30th Jun 20117:00 amRNSAGM Statement
23rd Mar 20117:00 amRNSFinal Results
11th Mar 201112:34 pmRNSRevised date for Results
1st Mar 201112:50 pmRNSNotice of Results
24th Dec 20107:00 amRNSTrading Statement
8th Nov 20104:53 pmRNSDirector/PDMR Shareholding
1st Nov 20107:00 amRNSAppointment of New Non-Executive Director
19th Oct 201010:07 amRNSProduct Update
12th Oct 20109:37 amRNSLaunches new transporter assay for BCRP
1st Oct 20107:00 amRNSCyprotex officially open new toxicology laboratory
16th Sep 20107:00 amRNSCyprotex and TB Alliance form collaboration
1st Sep 20107:00 amRNSProvides free online access to Cloe Knowledge
20th Aug 20107:00 amRNSCyprotex Adds In Vitro Toxicology Services
19th Aug 20109:30 amRNSHolding(s) in Company
18th Aug 20103:30 pmRNSHolding(s) in Company
18th Aug 20103:18 pmRNSHolding(s) in Company
18th Aug 20102:16 pmRNSDirector/PDMR Shareholding - amendment
18th Aug 20107:00 amRNSDirector/PDMR Shareholding
12th Aug 20107:00 amRNSHalf Yearly Report
6th Aug 20107:00 amRNSAcquisition of Apredica
14th Jul 20103:05 pmRNSResult of AGM
14th Jul 20107:00 amRNSAGM Statement
2nd Jul 20107:00 amRNSChange of Adviser

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.